[go: up one dir, main page]

MX2024003178A - Anticuerpos contra el lif y usos de los mismos. - Google Patents

Anticuerpos contra el lif y usos de los mismos.

Info

Publication number
MX2024003178A
MX2024003178A MX2024003178A MX2024003178A MX2024003178A MX 2024003178 A MX2024003178 A MX 2024003178A MX 2024003178 A MX2024003178 A MX 2024003178A MX 2024003178 A MX2024003178 A MX 2024003178A MX 2024003178 A MX2024003178 A MX 2024003178A
Authority
MX
Mexico
Prior art keywords
antibodies against
lif
against lif
antibodies
document
Prior art date
Application number
MX2024003178A
Other languages
English (en)
Inventor
Suarez Joan Seoane
Johan Fransson
Folgueira Judit Anido
Swetha Raman
Jean - Philippe JULIEN
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2024003178A publication Critical patent/MX2024003178A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se describen los anticuerpos que se dirigen al factor inhibidor de la leucemia (LIF). En el presente documento también se describen los usos de estos anticuerpos para el tratamiento del cáncer.
MX2024003178A 2016-12-19 2019-06-19 Anticuerpos contra el lif y usos de los mismos. MX2024003178A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
EP17382683 2017-10-13

Publications (1)

Publication Number Publication Date
MX2024003178A true MX2024003178A (es) 2024-03-25

Family

ID=67138942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007376A MX2019007376A (es) 2016-12-19 2017-12-18 Anticuerpos contra el lif y usos de los mismos.
MX2024003178A MX2024003178A (es) 2016-12-19 2019-06-19 Anticuerpos contra el lif y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019007376A MX2019007376A (es) 2016-12-19 2017-12-18 Anticuerpos contra el lif y usos de los mismos.

Country Status (23)

Country Link
US (2) US11390670B2 (es)
EP (2) EP3555132B1 (es)
JP (3) JP7100056B2 (es)
KR (3) KR102599557B1 (es)
CN (2) CN111868086B (es)
AU (1) AU2017381585B2 (es)
BR (1) BR112019012691A2 (es)
CA (1) CA3047528A1 (es)
CL (2) CL2019001717A1 (es)
DK (1) DK3555132T3 (es)
ES (1) ES2971126T3 (es)
FI (1) FI3555132T3 (es)
HR (1) HRP20240195T8 (es)
HU (1) HUE065241T2 (es)
IL (2) IL267450B (es)
LT (1) LT3555132T (es)
MX (2) MX2019007376A (es)
PL (1) PL3555132T3 (es)
RS (1) RS65187B1 (es)
SA (1) SA519402119B1 (es)
SI (1) SI3555132T1 (es)
SM (1) SMT202400065T1 (es)
ZA (1) ZA201904533B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012691A2 (pt) * 2016-12-19 2019-11-19 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats anticorpos contra a lif e seus usos
US20210130453A1 (en) * 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
JP2023504642A (ja) * 2019-12-04 2023-02-06 メドイミューン・リミテッド Ｌｉｆに対する抗体及びその使用
TW202128748A (zh) * 2020-01-24 2021-08-01 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
CN117043189A (zh) 2020-12-31 2023-11-10 诺纳生物（苏州）有限公司 人lifr抗原结合蛋白及其制备方法和应用
AR125855A1 (es) * 2021-05-14 2023-08-16 Genentech Inc Agonistas de trem2

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
AU4241693A (en) 1992-05-15 1993-12-13 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
JPH11504332A (ja) 1995-04-24 1999-04-20 ジェネンテク・インコーポレイテッド 白血病抑制因子およびエンドテリンアンタゴニストの用途
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
ZA200709291B (en) * 2005-04-25 2009-01-28 Pfizer Antibodies to myostatin
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20110135645A1 (en) 2006-10-04 2011-06-09 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
JP2012508017A (ja) * 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SG10201809779RA (en) 2013-03-11 2018-12-28 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
EP3037434B1 (en) 2013-08-20 2018-07-18 Japan Science and Technology Agency Human antibody kappa type light chain complex-containing composition and method for producing same
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
EP3049110A2 (en) 2013-09-23 2016-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
AU2014331923B2 (en) 2013-10-09 2020-02-06 Research Development Foundation Monoclonal Olfml-3 antibodies and uses thereof
TWI486172B (zh) 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
CN106471010A (zh) 2014-03-19 2017-03-01 建新公司 靶向模块的位点特异性糖工程化
EP3191129A4 (en) 2014-09-10 2018-03-14 The Regents of The University of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
BR112019012691A2 (pt) * 2016-12-19 2019-11-19 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats anticorpos contra a lif e seus usos
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
US20210130453A1 (en) * 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
MA52299A (fr) * 2018-06-18 2021-04-21 Fundacio Inst Catalana De Recerca I Estudis Avancats Procédés d'amélioration de la réponse à un traitement par anticorps anti-lif chez des individus atteints d'un cancer

Also Published As

Publication number Publication date
IL267450A (en) 2019-08-29
EP3555132A1 (en) 2019-10-23
CL2021000950A1 (es) 2021-11-26
SI3555132T1 (sl) 2024-04-30
BR112019012691A2 (pt) 2019-11-19
LT3555132T (lt) 2024-02-26
KR20240149987A (ko) 2024-10-15
ZA201904533B (en) 2024-08-28
KR102784394B1 (ko) 2025-03-19
IL294088B1 (en) 2023-06-01
HUE065241T2 (hu) 2024-05-28
CN111868086B (zh) 2024-07-16
EP3555132B1 (en) 2023-11-15
JP2020512388A (ja) 2020-04-23
FI3555132T3 (fi) 2024-02-08
PL3555132T3 (pl) 2024-04-22
ES2971126T3 (es) 2024-06-03
IL294088B2 (en) 2023-10-01
RS65187B1 (sr) 2024-03-29
CN111868086A (zh) 2020-10-30
SMT202400065T1 (it) 2024-03-13
NZ755004A (en) 2025-08-29
EP4321219A2 (en) 2024-02-14
JP2024075682A (ja) 2024-06-04
AU2017381585A1 (en) 2019-07-18
MX2019007376A (es) 2020-02-07
EP4321219A3 (en) 2024-05-15
DK3555132T3 (da) 2024-02-05
HRP20240195T1 (hr) 2024-04-26
JP7100056B2 (ja) 2022-07-12
AU2017381585B2 (en) 2025-02-13
CN118652335A (zh) 2024-09-17
KR20190122652A (ko) 2019-10-30
US20190352389A1 (en) 2019-11-21
US20230042095A1 (en) 2023-02-09
KR102716931B1 (ko) 2024-10-15
US11390670B2 (en) 2022-07-19
SA519402119B1 (ar) 2023-02-19
JP7459173B2 (ja) 2024-04-01
KR20230125099A (ko) 2023-08-28
JP2022130632A (ja) 2022-09-06
KR102599557B1 (ko) 2023-11-07
IL294088A (en) 2022-08-01
CL2019001717A1 (es) 2020-02-28
CA3047528A1 (en) 2018-06-28
IL267450B (en) 2022-07-01
HRP20240195T8 (hr) 2024-05-24

Similar Documents

Publication Publication Date Title
MX2024003178A (es) Anticuerpos contra el lif y usos de los mismos.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
ECSP17073743A (es) Moduladores de k-ras
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
UY37621A (es) Arn terapéutico que codifica citoquinas
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX373341B (es) INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS.
CL2017002606A1 (es) Inhibidor de bromodominio
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2017001171A1 (es) Peptidos macrocíclicos útiles como inmunomoduladores
MX2019000216A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX2016012880A (es) Cadena j modificada.
EA201691916A1 (ru) Биарильные ингибиторы киназы
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2016014555A (es) Composiciones novedosas, usos y metodos para hacerlas.
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
DOP2021000113A (es) Anticuerpos antiperiostina y usos de estos
DK3449008T3 (da) In vitro-fremgangsmåde til identificering af bugspytkirtelkræft eller intraduktal papillær mucinøs neoplasma i bugspytkirtlen